Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.
Xuefeng Li, Yan Yu, Hongbin Yu, Mengran Chen, Xin Zhang, Yu Wu
PURPOSE: Minimal residual disease (MRD) is a validated prognostic factor in several hematological malignancies. However, its role in systemic light chain (AL) amyloidosis remains controversial, and this systematic review and meta-analysis aims to fill this gap. METHODS: We searched for relevant studies on Pubmed, Embase, and Cochrane Controlled Register of Trials, nine studies involving 451 patients were included and meta-analyzed. This systematic review has been registered in PROSPERO (CRD42023494169)...
April 15, 2024: Journal of Cancer Research and Clinical Oncology
#2
JOURNAL ARTICLE
Xiuyun Zhang, Junpeng Hou, Guangyuan Zhou, Haixia Wang, Zeang Wu
PURPOSE: Kidney clear cell carcinoma (KIRC) has a poor prognosis, high morbidity and mortality rates, and high invasion and metastasis rate, and effective therapeutic targets are lacking. zDHHC3 has been implicated in various cancers, but its specific role in KIRC remains unclear. METHODS: In this study, we performed a pan-cancer analysis, bioinformatics analysis, and cell experiment to detect the role of zDHHC3 in KIRC. RESULTS: zDHHC3 was significantly down-regulated in KIRC, and that its high expression was associated with favorable patient outcomes...
April 15, 2024: Journal of Cancer Research and Clinical Oncology
#3
JOURNAL ARTICLE
Jincong Li, Yuxuan Song, Yun Peng, Jiaxing Lin, Yiqing Du, Caipeng Qin, Tao Xu
OBJECTIVE: To date, there have been few studies examining the prognostic implications of histological subtypes in ureteral cancer. And chemotherapy plays a crucial role in the treatment of ureteral cancer, while many factors influence the efficacy of chemotherapy. This study aimed to utilize the Surveillance, Epidemiology and End Results database to assess the impact of histological type on ureteral cancer prognostic outcomes and discovered how histological type and T-stage influence the efficacy of chemotherapy...
April 13, 2024: Journal of Cancer Research and Clinical Oncology
#4
JOURNAL ARTICLE
Franziska Springer, Anja Mehnert-Theuerkauf, Claudia Gebhardt, Jens-Uwe Stolzenburg, Susanne Briest
PURPOSE: Recognizing unmet care needs among cancer patients is crucial for improving a person-centered and tailored approach to survivorship care. This study aimed to explore the prevalence of unmet supportive care needs, pinpointing entity-specific areas of burden, and to identify factors associated with unmet needs within a diverse sample of cancer patients. METHODS: In this cross-sectional sub-study of a large multicenter study, 944 adult cancer patients reported supportive care needs via the well-validated SCNS...
April 12, 2024: Journal of Cancer Research and Clinical Oncology
#5
JOURNAL ARTICLE
Cordula Gebel, Bianka Ditscheid, Franziska Meissner, Ekaterina Slotina, Isabel Kruschel, Ursula Marschall, Ullrich Wedding, Antje Freytag
BACKGROUND: Palliative care (PC) contributes to improved end-of-life care for patients with hematologic malignancies (HM) and solid tumors (ST) by addressing physical and psychological symptoms and spiritual needs. Research on PC in HM vs. ST patients is fragmented and suggests less use. METHODS: We analyzed claims data of all deceased members of a large German health insurance provider for the year before death. First, we analyzed the frequency and the beginning of different types of PC and compared patients with HM vs...
April 12, 2024: Journal of Cancer Research and Clinical Oncology
#6
JOURNAL ARTICLE
Jie Tian, Yong-Ping Song, Gao-Chong Zhang, Shu-Fang Wang, Xiao-Xiang Chu, Ye Chai, Chun-Ling Wang, Ai-Li He, Feng Zhang, Xu-Liang Shen, Wei-Hua Zhang, Lin-Hua Yang, Da-Nian Nie, Dong-Mei Wang, Huan-Ling Zhu, Da Gao, Shi-Feng Lou, Ze-Ping Zhou, Guo-Hong Su, Yan Li, Jin-Ying Lin, Qing-Zhi Shi, Gui-Fang Ouyang, Hong-Mei Jing, Sai-Juan Chen, Jian Li, Jian-Qing Mi
PURPOSE: The synergistic effects of combining arsenic compounds with imatinib against chronic myeloid leukemia (CML) have been established using in vitro data. We conducted a clinical trial to compare the efficacy of the arsenic realgar-indigo naturalis formula (RIF) plus imatinib with that of imatinib monotherapy in patients with newly diagnosed chronic phase CML (CP-CML). METHODS: In this multicenter, randomized, double-blind, phase 3 trial, 191 outpatients with newly diagnosed CP-CML were randomly assigned to receive oral RIF plus imatinib (n = 96) or placebo plus imatinib (n = 95)...
April 11, 2024: Journal of Cancer Research and Clinical Oncology
#7
JOURNAL ARTICLE
Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.
Xuan Wu, Xingru Zhao, Chao Zhou, Nan Wei, Zhiwei Xu, Xiaoju Zhang
BACKGROUND: We aimed to comprehensively analyze the clinical value of immune-related eRNAs-driven genes in lung adenocarcinoma (LUAD) and find the potential biomarkers for prognosis and therapeutic response to improve the survival of this malignant disease. MATERIALS AND METHODS: Pearson's correlation analysis was performed to identify the immune-related eRNAs-driven genes. Cox regression and least absolute shrinkage and selection operator (LASSO) analyses were used to construct this prognostic risk signature...
April 11, 2024: Journal of Cancer Research and Clinical Oncology
#8
JOURNAL ARTICLE
Christopher Schrecker, Falko Schulze, Jörg Trojan, Wolf Otto Bechstein, Stefan Zeuzem, Christine Koch
PURPOSE: Hepatocellular carcinoma (HCC) arises in individuals with underlying liver disease. Diagnosing the degree of hepatic fibrosis helps to determine the severity of the underlying liver disease and may influence therapeutic decisions in HCC patients. Non-invasive fibrosis scores can be used to estimate the degree of fibrosis in liver disease patients, but most of these scores were developed in patients with viral hepatitis and without HCC. This study explored the ability of the Fibrosis-4 Index (FIB-4), the AST/Platelet Ratio Index (APRI), and the AST/ALT ratio to diagnose or exclude advanced fibrosis (METAVIR F3/4 versus F0-2) in patients with early-intermediate, potentially resectable HCC...
April 11, 2024: Journal of Cancer Research and Clinical Oncology
#9
JOURNAL ARTICLE
Soojung Hong, Ju Hyun Lee, Ja Yoon Heo, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Jee Hyun Kim
PURPOSE: Medications regulating immune homeostasis and gut microbiota could affect the efficacy of immune checkpoint inhibitors (ICIs). This study aimed to investigate the impact of concurrent medications on the clinical outcomes of patients with cancer receiving ICI therapy in South Korea. METHODS: We identified patients newly treated with ICI for non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), and malignant melanoma (MM) between August 2017 and June 2020 from a nationwide database in Korea...
April 10, 2024: Journal of Cancer Research and Clinical Oncology
#10
REVIEW
Wei Li, Jingyao Zhu, Jiayuan Li, Yiyun Jiang, Jiuai Sun, Yan Xu, Hongzhi Pan, Yan Zhou, Jun Zhu
BACKGROUND: Extracellular vesicles (EVs) can mediate cell-to-cell communication and affect various physiological and pathological processes in both parent and recipient cells. Currently, extensive research has focused on the EVs derived from cell cultures and various body fluids. However, insufficient attention has been paid to the EVs derived from tissues. Tissue EVs can reflect the microenvironment of the specific tissue and the cross-talk of communication among different cells, which can provide more accurate and comprehensive information for understanding the development and progression of diseases...
April 10, 2024: Journal of Cancer Research and Clinical Oncology
#11
JOURNAL ARTICLE
Yun Wang, Deng Lyu, Chao Cheng, Taohu Zhou, Wenting Tu, Yi Xiao, Changjing Zuo, Li Fan, Shiyuan Liu
PURPOSE: This study aims to assess the predictive value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) radiological features and the maximum standardized uptake value (SUVmax ) in determining the presence of spread through air spaces (STAS) in clinical-stage IA non-small cell lung cancer (NSCLC). METHODS: A retrospective analysis was conducted on 180 cases of NSCLC with postoperative pathological assessment of STAS status, spanning from September 2019 to September 2023...
April 10, 2024: Journal of Cancer Research and Clinical Oncology
#12
REVIEW
Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves E Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andrade Mota, Bruno Santucci, Daniel da Motta Girardi, Daniel Herchenhorn, Daniel Vilarim Araújo, Denis Leonardo Jardim, Diogo Assed Bastos, Diogo Rodrigues Rosa, Fabio A Schutz, Fábio Roberto Kater, Felipe da Silva Marinho, Fernando Cotait Maluf, Fernando Nunes Galvão de Oliveira, Fernando Vidigal, Igor Alexandre Protzner Morbeck, Jose Augusto Rinck Júnior, Leonardo Atem G A Costa, Manuel Caitano Dias Ferreira Maia, Manuela Zereu, Marcelo Roberto Pereira Freitas, Mariane Sousa Fontes Dias, Milena Shizue Tariki, Pamela Muniz, Patrícia Medeiros Milhomem Beato, Paulo Sérgio Moraes Lages, Pedro Isaacsson Velho, Ricardo Saraiva de Carvalho, Rodrigo Coutinho Mariano, Sandro Roberto de Araújo Cavallero, Thiago Martins Oliveira, Vinicius Carrera Souza, Oren Smaletz, Stênio de Cássio Zequi
PURPOSE: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. METHODS: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours...
April 9, 2024: Journal of Cancer Research and Clinical Oncology
#13
MULTICENTER STUDY
Yosuke Hirasawa, Takahiro Adachi, Takeshi Hashimoto, Wataru Fukuokaya, Yuhei Koike, Yuji Yata, Kazumasa Komura, Taizo Uchimoto, Takuya Tsujino, Kazuki Nishimura, Kiyoshi Takahara, Masanobu Saruta, Kazutoshi Fujita, Mamoru Hashimoto, Hirotsugu Uemura, Ryoichi Shiroki, Takashi Azuma, Takahiro Kimura, Yoshio Ohno
OBJECTIVES: Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in efficacy of EV after each ICIs and prognostic factors are not well known. We aimed to compare the efficacy of EV in patients with metastatic UC who were treated with avelumab or pembrolizumab and to identify the prognostic factors. METHODS: The records of 100 patients with advanced metastatic UC who received EV after the administration of either avelumab or pembrolizumab were retrospectively collected from five academic hospitals in Japan...
April 9, 2024: Journal of Cancer Research and Clinical Oncology
#14
JOURNAL ARTICLE
Jing Chen, Jie Zhou, Fei Cheng, Donghe Chen, Fangshu Guan, Enfan Zhang, Jingsong He, Zhen Cai, Yi Zhao
PURPOSE: To explore the prognostic and therapeutic role of Epstein-Barr Virus (EBV) on peripheral T-cell lymphoma (PTCL). METHODS: Totally 262 newly diagnosed PTCL patients who were hospitalized from January 2014 to December 2022 were retrospectively enrolled. Molecular analysis included 31 eligible patients. EBV-encoded RNA (EBER) presence in tumor tissue and EBV DNA levels in patients at baseline (DNA1) and after 4 cycles of chemotherapy (DNA4) were assessed. RESULTS: Our findings revealed that the EBER-positive cohort exhibited significant differences compared to counterparts in overall survival (OS, P = 0...
April 8, 2024: Journal of Cancer Research and Clinical Oncology
#15
JOURNAL ARTICLE
Wen Hao, Wenjing Liu, Ruimin Chang, Mi Yang, Kai Xin, Jingxin Liu, Yibing Wang, Meijin Ren, Jiaqi Xie, Yang Yang
BACKGROUND: To evaluate the clinical efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer in the real world. METHODS: The retrospective analysis was conducted on the clinical records of 402 patients with advanced gastric cancer who were admitted to the Nanjing Drum Tower Hospital between December 2017 and April 2022 and who had received immunotherapy. Observation target: drug use, treatment, adverse reaction type and grade, objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), and overall survival (OS)...
April 8, 2024: Journal of Cancer Research and Clinical Oncology
#16
JOURNAL ARTICLE
Lu Zhao, Jia Huang, Wenting Liu, Xiaoyan Su, Bei Zhao, Xianggang Wang, Xiaoju He
PURPOSE: The present study aims to determine the molecular mechanism mediated by RAD51 antisense RNA 1 (RAD51-AS1) in ovarian cancer (OvCA). METHODS: The data associated with RAD51-AS1 in OvCA were obtained from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database. Relative expression of RAD51-AS1 was detected. Determination of cell proliferation, metastasis, and invasion was performed by cell counting, colony formation, would-healing, and transwell invasion assays...
April 7, 2024: Journal of Cancer Research and Clinical Oncology
#17
JOURNAL ARTICLE
David Gorodezki, Julian Zipfel, Andrea Bevot, Thomas Nägele, Martin Ebinger, Martin U Schuhmann, Jens Schittenhelm
PURPOSE: The prognostic utility of MIB-1 labeling index (LI) in pediatric low-grade glioma (PLGG) has not yet conclusively been described. We assess the correlation of MIB-1 LI and tumor growth velocity (TGV), aiming to contribute to the understanding of clinical implications and the predictive value of MIB-1 LI as an indicator of proliferative activity and progression-free survival (PFS) in PLGG. METHODS: MIB-1 LI of a cohort of 172 nonependymal PLGGs were comprehensively characterized...
April 5, 2024: Journal of Cancer Research and Clinical Oncology
#18
REVIEW
Yuanyuan Chen, Hualian Liu, Yadong Sun
When it comes to the diagnosis of solid tumors, biopsy is always the gold standard. However, traumatic and inflammatory stimuli are so closely related to tumor initiation and development that the acute inflammatory response induced by biopsy can give rise to changes in the tumor microenvironment, including recruitment of immunosuppressive cells (M2 macrophages, Treg cells, Tumor-associated neutrophils) and secretion of inflammation-associated cytokines, to create immunosuppressive conditions that enable the increase of circulating tumor cells in the peripheral circulation and promote the metastatic spread of tumors after surgery...
April 5, 2024: Journal of Cancer Research and Clinical Oncology
#19
JOURNAL ARTICLE
Yujun Cui, Maxiaowei Song, Jian Tie, Shuai Li, Hongzhi Wang, Yangzi Zhang, Jianhao Geng, Zhiyan Liu, Huajing Teng, Xin Sui, Xianggao Zhu, Yong Cai, Yongheng Li, Weihu Wang
PURPOSE: Residual lymph node metastases (RLNM) remained a great concern in the implementation of organ-preserving strategies and led to poor prognosis in locally advanced rectal cancer (LARC). In this study, we aimed to identify the clinicopathological factors correlated with RLNM in LARC patients with ypT0-2 after neoadjuvant chemoradiotherapy (NCRT). METHODS: We retrospectively analyzed 417 patients histologically diagnosed middle-low LARC after NCRT and total mesorectal excision (TME), whose pathological staging was ypT0-2...
April 4, 2024: Journal of Cancer Research and Clinical Oncology
#20
REVIEW
Renshan Zhao, Xiaomin Guan, Peng Zhang, Yunpeng Liu, Yinghui Xu, Chao Sun, Shi Qiu, Wenhao Zhu, Zhiguang Yang, Xu Wang
BACKGROUND: The advent of immune checkpoint inhibitors has dramatically changed the treatment paradigm for advanced non-small-cell lung cancer (NSCLC). Due to the complexity and diversity of stage III disease, the inclusion of immune checkpoint inhibitors (ICIs) in neoadjuvant treatment regimens is also required. However, immune-related adverse events (irAEs) limit the application of ICIs to a certain extent. Bronchopleural fistula (BPF) is a serious and fatal complication after pneumonectomy that is rarely reported, especially in patients who accept neoadjuvant immunotherapy or chemoimmunotherapy...
April 4, 2024: Journal of Cancer Research and Clinical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
